Polaryx Therapeutics, Inc. Noninterest Expense Investment Advisory Fees
Polaryx Therapeutics, Inc. (PLYX) reported Noninterest Expense Investment Advisory Fees of $467.00 thousand for the 1-month period ending 2024-10-31, per its 10-K filed 2026-03-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:NoninterestExpenseInvestmentAdvisoryFees · last filed 2026-03-24
- 2024-10-31: Noninterest Expense Investment Advisory Fees 1 month $467.00K.
| Period end | Noninterest Expense Investment Advisory Fees 1 month |
|---|---|
| 2024-10-31 | $467.00K 10-K · filed 2026-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |